Clinical Trial Update: CRF1 Antagonist GSK561679 in Alcoholism [Phase 2]

View source ↗

Summary

Phase 2 trial of the CRF1 receptor antagonist GSK561679 for alcohol dependence has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alcohol Dependence

Drugs mentioned

• GSK561679 (GSK561679)

Snippet

Sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Conditions: Alcohol Dependence | Phase 2 | Status: COMPLETED | Results posted: 2016-11-07